Nasal spray with antibodies against SARS-CoV-2, which helps to prevent the spread of the virus.

    Read more



    Profemina intimate cream
    (available soon)

    Probiotic cream for women health. Lactobacillus crispatus

    Read more



    Profemina probiotic capsules
    (available soon)

    Probiotic capsules for women health. Lactobacillus crispatus


Research and Patent

Research and Patent

A USPTO patent application (No. 63/160,833) has been submitted by the product developers.

BioBlock antibody efficiency on Delta and Omicron

Colostrum immunoglobulin preparation blocks SARS-CoV-2 Spike protein binding to ACE2 receptor in ELISA assay

BioBlock antibody solution blocks SARS-CoV-2 virus entry into animal cells

In collaboration with Tartu University scientists, we tested BioBlock antibodies’ ability to block SARS-CoV-2 virus entry into Vero E6 cells

Results demonstrate that BioBlock antibodies are capable of blocking virus entry into the cells at concentration of 20 mg/ml

BioBlock nasal spray contains antibodies at concentration of 0,2 mg/ml

Immunoglobulins from immunized cows inhibit SARS-CoV-2 virus entry to Vero E6 cells in the cytopathic effect neutralization assay

Colostrum derived immunoglobulins from immunized cows neutralize pseudovirus displaying different Spike proteins of currently circulating SARS-CoV-2 variantsvariants

BioBlock antibody solution reduces the SARS-CoV-2 viral load found in Syrian Golden Hamsters lungs

Syrian Golden Hamsters (n=8) were administered BioBlock intranasally at two different concentrations (0.1 mg/mL and 0.2 mg/mL), followed by an infection of SARS-CoV-2 virus (105 pfu). After 4 days the lung viral titer was determined. BioBlock antibody solution reduces viral load even after a single intranasal administering dose. 

Antibodies in Bioblock remain on the human nasal mucosa at least 4 hours after administration

Eight people were administered 400 µl of BioBlock nasal spray solution. Filter paper piecer (15 µl)  were placed onto the nasal mucosa and the concentration of bovine antibodies was measured.

Clinical Trial Assessing the Efficacy and Safety of BioBlock®

Randomized, Controlled, Double-Blind Proof of Concept Trial Assessing the Efficacy and Safety of BioBlock® Intranasally Administered Virus-Neutralizing Bovine Colostrum Nasal Spray in Preventing  of COVID-19 Infection in Healthy Volunteer Individuals.

This is a randomized (1: 1) parallel study of a double-blind cluster of proof of concept. The randomization unit is healthy volunteers who have no symptoms of COVID-19 at baseline and have not been infected with SARS-CoV-2 for the past 90 days. Selected subjects are be randomly assigned to either an experimental group (subjects using BioBlock® Antiviral Nasal Spray immediately after waking up in the morning and once every 4 hours thereafter for 28 days) or a control group (subjects using placebo immediately after waking up in the morning and once every 4 hours thereafter and so within 28 days).

For both study groups, a rapid COVID-19 antigen test is scheduled twice weekly or for 4 consecutive weeks if symptoms of COVID-19 infection occur.

Cases of side effects are recorded during the study.

Indicative duration of the study is March 2022-August 2022